BeiGene, Ltd. (NASDAQ:BGNE) COO Sells $145,803.60 in Stock

BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) COO Xiaobin Wu sold 1,010 shares of the company’s stock in a transaction dated Tuesday, June 21st. The stock was sold at an average price of $144.36, for a total transaction of $145,803.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Xiaobin Wu also recently made the following trade(s):

• On Friday, June 17th, Xiaobin Wu sold 578 shares of BeiGene stock. The stock was sold at an average price of $139.60, for a total transaction of $80,688.80.
• On Monday, June 6th, Xiaobin Wu sold 3,410 shares of BeiGene stock. The shares were sold at an average price of $141.99, for a total transaction of $484,185.90.
• On Thursday, May 5th, Xiaobin Wu sold 6,725 shares of BeiGene stock. The stock was sold at an average price of $164.35, for a total transaction of $1,105,253.75.

Shares of NASDAQ BGNE opened at $155.68 on Thursday. The business has a 50-day moving average of $147.39 and a 200-day moving average of $198.61. The firm has a market capitalization of $16.03 billion, a price-to-earnings ratio of -7.75 and a beta of 0.87. BeiGene, Ltd. has a 12 month low of $118.18 and a 12 month high of $426.56. The company has a current ratio of 5.05, a quick ratio of 4.87 and a debt-to-equity ratio of 0.03.

BeiGene (NASDAQ:BGNE – Get Rating) last posted its earnings results on Thursday, May 5th. The company reported ($4.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.52) by $0.28. The firm had revenue of $306.60 million for the quarter, compared to analysts’ expectations of $300.41 million. BeiGene had a negative return on equity of 40.10% and a negative net margin of 218.25%. BeiGene’s revenue for the quarter was down 49.4% compared to the same quarter last year. On average, analysts predict that BeiGene, Ltd. will post -15.13 earnings per share for the current year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Pinebridge Investments L.P. purchased a new position in BeiGene during the 4th quarter valued at approximately $27,000. Koshinski Asset Management Inc. lifted its stake in shares of BeiGene by 139.6% during the 1st quarter. Koshinski Asset Management Inc. now owns 242 shares of the company’s stock worth $46,000 after acquiring an additional 141 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd lifted its stake in shares of BeiGene by 26.1% during the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 778 shares of the company’s stock worth $210,000 after acquiring an additional 161 shares during the last quarter. Laurel Wealth Advisors Inc. bought a new stake in BeiGene during the 4th quarter valued at $249,000. Finally, Blair William & Co. IL raised its position in BeiGene by 44.4% during the 4th quarter. Blair William & Co. IL now owns 1,083 shares of the company’s stock valued at $293,000 after purchasing an additional 333 shares in the last quarter.

Several equities research analysts have recently commented on the stock. Morgan Stanley lifted their price target on shares of BeiGene from $330.00 to $338.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 12th. SVB Leerink lowered shares of BeiGene from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $300.00 to $177.00 in a research report on Thursday, March 17th. Finally, StockNews.com downgraded shares of BeiGene from a “hold” rating to a “sell” rating in a report on Thursday, June 16th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, BeiGene has an average rating of “Moderate Buy” and an average target price of $315.33.

About BeiGene (Get Rating)

BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer therapeutics in the People's Republic of China, the United States, and internationally. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC).

Read More